Interleukin-1 receptor blockade rescues myocarditis-associated end-stage heart failure

Frontiers in Immunology

Volumn 8, Issue FEB, 2017, Pages

  Cavalli, Giulio ^a,b,c   Foppoli, Marco ^a   Cabrini, Luca ^a   Dinarello, Charles A ^b,c   Tresoldi, Moreno ^a   Dagna, Lorenzo ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Anakinra; Critical care; Cytokine; Heart failure; Inflammasome; Inflammation; Shock

Indexed keywords

ANAKINRA; C REACTIVE PROTEIN; DOBUTAMINE; FERRITIN; FUROSEMIDE; INTERLEUKIN 1 RECEPTOR; LACTATE DEHYDROGENASE;

AGED; ANEMIA; ARTICLE; CARDIOGENIC SHOCK; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTRANSAMINASEMIA; HYPOTENSION; INTRAAORTIC BALLOON PUMP; LEUKOCYTOSIS; LYMPHADENOPATHY; MALE; MYOCARDITIS; NEUTROPHILIA; NONINVASIVE VENTILATION; PHYSICAL EXAMINATION; T CELL LYMPHOMA; THROMBOCYTOPENIA; TRANSTHORACIC ECHOCARDIOGRAPHY;

EID: 85014407835     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2017.00131     Document Type: Article

References (37)

1. Kim B, Lee Y, Kim E, Kwak A, Ryoo S, Bae SH, et al. The interleukin-1alpha precursor is biologically active and is likely a key alarmin in the IL-1 family of cytokines. Front Immunol (2013) 4:391. doi: 10.3389/fimmu.2013.00391
2. Toldo S, Kannan H, Bussani R, Anzini M, Sonnino C, Sinagra G, et al. Formation of the inflammasome in acute myocarditis. Int J Cardiol (2014) 171(3):e119-21. doi:10.1016/j.ijcard.2013.12.137
3. Stoffels M, Zaal R, Kok N, van der Meer JW, Dinarello CA, Simon A. ATP-induced IL-1beta specific secretion: true under stringent conditions. Front Immunol (2015) 6:54. doi:10.3389/fimmu.2015.00054
4. Jain A, Kaczanowska S, Davila E. IL-1 receptor-associated kinase signaling and its role in inflammation, cancer progression, and therapy resistance. Front Immunol (2014) 5:553. doi:10.3389/fimmu.2014.00553
5. Garlanda C, Mantovani A. Ligands and receptors of the interleukin-1 family in immunity and disease. Front Immunol (2013) 4:396. doi:10.3389/fimmu.2013.00396
6. Cavalli G, Koenders M, Kalabokis V, Kim J, Tan AC, Garlanda C, et al. Treating experimental arthritis with the innate immune inhibitor interleukin-37 reduces joint and systemic inflammation. Rheumatology (2016) 55(12):2220-9. doi:10.1093/rheumatology/kew325
7. Abbate A. The heart on fire: inflammasome and cardiomyopathy. Exp Physiol (2013) 98(2):385. doi:10.1113/expphysiol.2012.069021
8. Cavalli G, Biavasco R, Borgiani B, Dagna L. Oncogene-induced senescence as a new mechanism of disease: the paradigm of erdheim-chester disease. Front Immunol (2014) 5:281. doi:10.3389/fimmu.2014.00281
9. Cavalli G, Guglielmi B, Berti A, Campochiaro C, Sabbadini MG, Dagna L. The multifaceted clinical presentations and manifestations of Erdheim-Chester disease: comprehensive review of the literature and of 10 new cases. Ann Rheum Dis (2013) 72(10):1691-5. doi:10.1136/annrheumdis-2012-202542
10. Campochiaro C, Tomelleri A, Cavalli G, Berti A, Dagna L. Erdheim-Chester disease. Eur J Intern Med (2015) 26(4):223-9. doi:10.1016/j.ejim.2015.03.004
11. Lopetuso LR, Chowdhry S, Pizarro TT. Opposing functions of classic and novel IL-1 family members in gut health and disease. Front Immunol (2013) 4:181. doi:10.3389/fimmu.2013.00181
12. van de Veerdonk FL, Netea MG. New insights in the immunobiology of IL-1 family members. Front Immunol (2013) 4:167. doi:10.3389/fimmu.2013.00167
13. Cavalli G, Dinarello CA. Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies. Rheumatology (Oxford) (2015) 54(12):2134-44. doi:10.1093/rheumatology/kev269
14. Raffeiner B, Botsios C, Dinarello CA, Ometto F, Punzi L, Ramonda R. Adult-onset Still's disease with myocarditis successfully treated with the interleukin-1 receptor antagonist anakinra. Joint Bone Spine (2011) 78(1):100-1. doi:10.1016/j.jbspin.2010.09.014
15. Cavalli G, Franchini S, Aiello P, Guglielmi B, Berti A, Campochiaro C, et al. Efficacy and safety of biological agents in adult-onset Still's disease. Scand J Rheumatol (2015) 44(4):309-14. doi:10.3109/03009742.2014.992949
16. Movva R, Brown SB, Morris DL, Figueredo VM. Anakinra for myocarditis in juvenile idiopathic arthritis. Tex Heart Inst J (2013) 40(5):623-5.
17. Choi AD, Moles V, Fuisz A, Weissman G. Cardiac magnetic resonance in myocarditis from adult onset Still's disease successfully treated with anakinra. Int J Cardiol (2014) 172(1):e225-7. doi:10.1016/j.ijcard.2013.12.151
18. Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood (2011) 117(14):3720-32. doi:10.1182/blood-2010-07-273417
19. Diddle JW, Almodovar MC, Rajagopal SK, Rycus PT, Thiagarajan RR. Extracorporeal membrane oxygenation for the support of adults with acute myocarditis. Crit Care Med (2015) 43(5):1016-25. doi:10.1097/CCM.0000000000000920
20. Rajagopal SK, Almond CS, Laussen PC, Rycus PT, Wypij D, Thiagarajan RR. Extracorporeal membrane oxygenation for the support of infants, children, and young adults with acute myocarditis: a review of the Extracorporeal Life Support Organization registry. Crit Care Med (2010) 38(2):382-7. doi:10.1097/CCM.0b013e3181bc8293
21. Cavalli G, Pappalardo F, Mangieri A, Dinarello CA, Dagna L, Tresoldi M. Treating life-threatening myocarditis by blocking interleukin-1. Crit Care Med (2016) 44(8):e751-4. doi:10.1097/CCM.0000000000001654
22. Tong H, Ren Y, Liu H, Xiao F, Mai W, Meng H, et al. Clinical characteristics of T-cell lymphoma associated with hemophagocytic syndrome: comparison of T-cell lymphoma with and without hemophagocytic syndrome. Leuk Lymphoma (2008) 49(1):81-7. doi:10.1080/10428190701713630
23. Cavalli G, Fallanca F, Dinarello CA, Dagna L. Treating pulmonary silicosis by blocking interleukin 1. Am J Respir Crit Care Med (2015) 191(5):596-8. doi:10.1164/rccm.201412-2150LE
24. Abbate A, Kontos MC, Grizzard JD, Biondi-Zoccai GG, Van Tassell BW, Robati R, et al. Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). Am J Cardiol (2010) 105(10):1371-1377e1371. doi:10.1016/j.amjcard.2009.12.059
25. Abbate A, Van Tassell BW, Biondi-Zoccai G, Kontos MC, Grizzard JD, Spillman DW, et al. Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study]. Am J Cardiol (2013) 111(10):1394-400. doi:10.1016/j.amjcard.2013.01.287
26. Morton AC, Rothman AM, Greenwood JP, Gunn J, Chase A, Clarke B, et al. The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study. Eur Heart J (2015) 36(6):377-84. doi:10.1093/eurheartj/ehu272
27. Cain BS, Meldrum DR, Dinarello CA, Meng X, Joo KS, Banerjee A, et al. Tumor necrosis factor-a and interleukin-1b synergistically depress human myocardial function. Crit Care Med (1999) 27(7):1309-18. doi:10.1097/00003246-199907000-00018
28. Van Tassell BW, Arena RA, Toldo S, Mezzaroma E, Azam T, Seropian IM, et al. Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure. PLoS One (2012) 7(3):e33438. doi:10.1371/journal.pone.0033438
29. Van Tassell BW, Arena R, Biondi-Zoccai G, McNair Canada J, Oddi C, Abouzaki NA, et al. Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART Pilot Study). Am J Cardiol (2014) 113(2):321-7. doi:10.1016/j.amjcard.2013.08.047
30. Ikonomidis I, Lekakis JP, Nikolaou M, Paraskevaidis I, Andreadou I, Kaplanoglou T, et al. Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis. Circulation (2008) 117(20):2662-9. doi:10.1161/CIRCULATIONAHA.107.731877
31. Mirabel M, Luyt CE, Leprince P, Trouillet JL, Léger P, Pavie A, et al. Outcomes, long-term quality of life, and psychologic assessment of fulminant myocarditis patients rescued by mechanical circulatory support. Crit Care Med (2011) 39(5):1029-35. doi:10.1097/CCM.0b013e31820ead45
32. McCarthy RE III, Boehmer JP, Hruban RH, Hutchins GM, Kasper EK, Hare JM, et al. Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med (2000) 342(10):690-5. doi:10.1056/NEJM200003093421003
33. Rose NR. Viral myocarditis. Curr Opin Rheumatol (2016) 28(4):383-9. doi:10.1097/BOR.0000000000000303
34. Opal SM, Fisher CJ Jr, Dhainaut JF, Vincent J-L, Brase R, Lowry SF, et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. Crit Care Med (1997) 25:1115-24. doi:10.1097/00003246-199707000-00010
35. Fisher CJ Jr, Slotman GJ, Opal SM, Pribble JP, Bone RC, Emmanuel G, et al. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit Care Med (1994) 22:12-21. doi:10.1097/00003246-199401000-00008
36. Fisher CJ Jr, Dhainaut JF, Opal SM, Pribble JP, Balk RA, Slotman GJ, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA (1994) 271(23):1836-43. doi:10.1001/jama.271.23.1836
37. Shakoory B, Carcillo JA, Chatham WW, Amdur RL, Zhao H, Dinarello CA, et al. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial. Crit Care Med (2016) 44(2):275-81. doi:10.1097/CCM.0000000000001402